AU784416B2 - Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof - Google Patents

Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof Download PDF

Info

Publication number
AU784416B2
AU784416B2 AU50359/00A AU5035900A AU784416B2 AU 784416 B2 AU784416 B2 AU 784416B2 AU 50359/00 A AU50359/00 A AU 50359/00A AU 5035900 A AU5035900 A AU 5035900A AU 784416 B2 AU784416 B2 AU 784416B2
Authority
AU
Australia
Prior art keywords
pharmacologically active
active agent
composition
paclitaxel
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU50359/00A
Other languages
English (en)
Other versions
AU5035900A (en
Inventor
Neil P Desai
Leslie Louie
Shlomo Magdassi
Patrick Soon-Shiong
Chunlin Tao
Andrew Yang
Zhiwen Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
American Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by American Bioscience Inc filed Critical American Bioscience Inc
Publication of AU5035900A publication Critical patent/AU5035900A/en
Application granted granted Critical
Publication of AU784416B2 publication Critical patent/AU784416B2/en
Priority to AU2006202836A priority Critical patent/AU2006202836B2/en
Assigned to ABRAXIS BIOSCIENCE, LLC reassignment ABRAXIS BIOSCIENCE, LLC Alteration of Name(s) in Register under S187 Assignors: AMERICAN BIOSCIENCES, INC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU50359/00A 1999-05-21 2000-05-19 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof Expired AU784416B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006202836A AU2006202836B2 (en) 1999-05-21 2006-06-30 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US09/316642 1999-05-21
PCT/US2000/013954 WO2000071079A2 (en) 1999-05-21 2000-05-19 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202836A Division AU2006202836B2 (en) 1999-05-21 2006-06-30 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Publications (2)

Publication Number Publication Date
AU5035900A AU5035900A (en) 2000-12-12
AU784416B2 true AU784416B2 (en) 2006-03-30

Family

ID=23229970

Family Applications (3)

Application Number Title Priority Date Filing Date
AU50359/00A Expired AU784416B2 (en) 1999-05-21 2000-05-19 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU2006202836A Expired AU2006202836B2 (en) 1999-05-21 2006-06-30 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU2009217409A Abandoned AU2009217409A1 (en) 1999-05-21 2009-09-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2006202836A Expired AU2006202836B2 (en) 1999-05-21 2006-06-30 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU2009217409A Abandoned AU2009217409A1 (en) 1999-05-21 2009-09-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Country Status (5)

Country Link
EP (1) EP1178786A4 (zh)
AU (3) AU784416B2 (zh)
CA (2) CA2684454A1 (zh)
HK (1) HK1045646A1 (zh)
WO (1) WO2000071079A2 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
KR20030019296A (ko) * 1999-10-27 2003-03-06 아이박스 리서치 인코포레이티드 인체 환자에게 탁산을 경구 투여하는 방법 및 조성물
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20030087837A1 (en) * 2001-10-15 2003-05-08 Jonas Jeffrey M. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (sl) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
EP1834624A4 (en) * 2005-01-07 2011-05-04 Eisai R&D Man Co Ltd MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
LT3248600T (lt) 2005-02-18 2020-07-27 Abraxis Bioscience, Llc Terapinių agentų deriniai bei įvedimo būdai ir kombinuotas gydymas
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
CA2620585C (en) * 2005-08-31 2015-04-28 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP1962906A4 (en) * 2005-10-21 2009-11-18 Panacea Biotec Ltd PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ANTICREME AND AT LEAST ONE POLYMER
US8980323B2 (en) 2006-08-29 2015-03-17 Fujifilm Corporation Hydrophilic matrix containing poorly water-soluble compound and method for producing the same
WO2008076373A1 (en) 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP2010520289A (ja) 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
KR20100048751A (ko) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 스프레이 가능한 캡슐화된 기능성 미립자 조성물과 그 제조방법
WO2010060811A2 (en) * 2008-11-27 2010-06-03 Basf Se Surface active proteins as excipients in solid pharmaceutical formulations
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
SI2419732T1 (sl) 2009-04-15 2020-03-31 Abraxis Bioscience, Llc Sestave nanodelcev brez prionov in metode za njihovo pripravo
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
MX346861B (es) 2010-03-26 2017-04-04 Abraxis Bioscience Llc * Metodos de tratamiento de carcinoma hepato celular.
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ706745A (en) 2010-06-04 2017-01-27 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2956002B1 (en) 2013-02-16 2017-09-06 Albumedix A/S Pharmacokinetic animal model
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
CN104548116A (zh) * 2013-10-11 2015-04-29 程树海 一种稳定的蛋白质载药微粒系统制备方法
WO2015018380A2 (en) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
DE102016125666A1 (de) * 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
EP3615011A4 (en) * 2017-04-24 2021-01-06 ZY Therapeutics Inc. PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER
CA3094453A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
WO2021119439A1 (en) * 2019-12-11 2021-06-17 The Regents Of The University Of Michigan Compositions and methods for systemic delivery of bcl-2 and bcl-xl antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
WO1998014174A1 (en) * 1996-10-01 1998-04-09 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
IL133672A0 (en) * 1997-06-27 2001-04-30 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
WO1998014174A1 (en) * 1996-10-01 1998-04-09 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
HK1045646A1 (zh) 2002-12-06
AU2006202836A1 (en) 2006-07-27
CA2684454A1 (en) 2000-11-18
CA2371912C (en) 2010-02-16
EP1178786A4 (en) 2006-03-01
EP1178786A1 (en) 2002-02-13
WO2000071079A2 (en) 2000-11-30
AU5035900A (en) 2000-12-12
WO2000071079A3 (en) 2008-03-27
CA2371912A1 (en) 2000-11-30
AU2006202836B2 (en) 2009-10-08
AU2009217409A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
AU784416B2 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP0961612B2 (en) Protein stabilized pharmacologically active agents and their use
US8137684B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070117863A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20080161382A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2272504A2 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU2002300723B2 (en) Novel Formulations of Pharmacological Agents, Methods for the Preparation Thereof and Methods for the Use Thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired